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Background: Knowledge of the level of healthcare utilization (HCU) and the predictors of high
HCU use in patients with an implantable cardioverter defibrillator (ICD) is lacking. We examined
the level of HCU and predictors associated with increased HCU in first-time ICD patients, using a
prospective study design.
Methods: ICD patients (N = 201) completed a set of questionnaires at baseline and 3, 6, and 12
months after inclusion. A hierarchicalmultiple linear regressionwith threemodelswas performed
to examine predictors of HCU.
Results: HCU was highest between baseline and 3 months postimplantation and gradually
decreased during 12 months follow-up. During the first year postimplantation, only depression
(𝛽 = 0.342, P = 0.002) was a significant predictor. Between baseline and 3 months follow-up,
younger age (𝛽 = −0.220, P < 0.01), New York Heart Association class III/IV (𝛽 = 0.705, P = 0.01),
and secondary indication (𝛽 = 0.148, P = 0.05) were independent predictors for increased HCU.
Between 3 and 6months follow-up, younger age (𝛽 =−0.151, P= 0.05) and depression (𝛽 = 0.370,
P < 0.001) predicted increased HCU. Between 6 and 12 months only depression (𝛽 = 0.355,
P= 0.001) remained a significant predictor.
Conclusions: Depression was an important predictor of increased HCU in ICD patients in the
first year postimplantation, particularly after 3months postimplantation. Identifying patientswho
need additional care and provide this on time might better meet patients’ needs and lower future
HCU.
K EYWORD S
depression, healthcare utilization, implantable cardioverter defibrillator, mental health
1 INTRODUCTION
The implantable cardioverter defibrillator (ICD) is the treatment of
choice for the prevention of potentially life-threatening cardiac tach-
yarrhythmias in high-risk patients (primary prevention) and in patients
whohaveexperienced cardiac tachyarrhythmias in thepast (secondary
prevention).1 The ICD constantly monitors the heart rate and in case
of a ventricular tachyarrhythmia delivers a shock in order to restore
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and nomodifications or adaptations aremade.
c© 2019 The Authors. Pacing and Clinical Electrophysiology published byWiley Periodicals, Inc.
a normal rhythm.2 Because of the proven benefits of the ICD as com-
pared to antiarrhythmic medication terminating tachyarrhythmias,3
the number of ICD implants has increased over the past years,
although a plateau now has been reached in at least many European
countries.4
Besides the unequivocal medical benefits, ICD therapy is asso-
ciated with a risk of complications and increased healthcare costs
have been reported.5 Receiving an ICD is associated with high
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healthcare costs as the implantation device itself can be as expensive
as 30 000 euros.6 In addition, after implantation, patients are gener-
ally followed-upat1-to-4-month intervals (dependingonpatients’ clin-
ical status and device model) at the outpatient clinic.2 These follow-
ups are generally performed by the ICD technicians but may also
involve a consult by the cardiologist in case of complications (eg,
wound infections, lead failure), whichmay result in even higher health-
care expenses.5 Besides patients’ medical needs with respect to liv-
ing with an ICD, a significant subgroup (1 in 5) reports symptoms of
anxiety and depression at a level that warrants treatment7 and that
affects patients’ physical andmental functioning.8 In turn, thismay lead
to a further increase in healthcare utilization (HCU) and associated
costs.
Previous studies have shown that an increase of HCU depends on
patients’ demographic, medical, and psychological characteristics (eg,
multimorbidity,mental health disorders).9 As someof these factors are
modifiable, it is important to timely identify this subset of patients at
the time of implantation and to provide patients with relevant care in
order to reduce HCU and associated costs. To the best of our knowl-
edge, no studies to date have examined the level of HCU and its pre-
dictors in the ICD population. Hence, in the current study we exam-
ined the level of HCU and the predictors of increased HCU and costs
in patients with an ICD.
2 METHODS
2.1 Participants and study procedure
Data for the current study have been collected as part of the WEB-
based distress management program for implantable CARdioverter
dEfibrillator patients (WEBCARE), which was a multicenter random-
ized controlled trial.10 The study sample consisted of patients who
were admitted for a first-time implantation of an ICD. Patients were
recruitedbetweenApril 2010andFebruary2013 fromsixDutch refer-
ral hospitals (Amphia Hospital, Breda; Canisius-Wilhelmina Hospital,
Nijmegen; Catharina Hospital, Eindhoven; Erasmus Medical Centre,
Rotterdam; Onze Lieve Vrouwe Gasthuis, Amsterdam; Vlietland Hos-
pital, Schiedam).
The ICD technician or ICD nurse of the participating hospitals
approached all patients between 18 and 75 years who received a
first-time ICD implant for participation. Exclusion criteria were a his-
tory of psychiatric illness other than depressive or anxiety disorders,
significant cognitive impairments (eg, dementia), being on the waiting
list for heart transplantation, life-threatening comorbidities (eg, malig-
nancies), life expectancy less than 1 year, lack of internet/computer
skills, and insufficient knowledge of the Dutch language. In the 1-year
follow-up period after the ICD implantation, patients were requested
to complete a set of validated and standardized questionnaires at
four time-points (baseline, 3, 6, and 12 months after inclusion). The
study procedure has been described elsewhere in more detail.10 The
study protocol was approved by theMedical Ethical Committees of all
participating centers and the study was conducted in accordance to
the Helsinki declaration.
2.2 Demographic and clinical variables
Information on demographic (age, gender, educational level) and clini-
cal variables (CharlsonComorbidity Index [CCI], NewYorkHeartAsso-
ciation [NYHA] functional class [NYHA-class I/II vs III/IV], ICD indica-
tion [primary vs secondary indication], and total shocks [appropriate
and inappropriate]) was obtained from purpose-designed questions in
the questionnaires and patients’ medical records.
2.3 Healthcare utilization
An adjusted version of the Trimbos/iMTA questionnaire for Costs
associated with Psychiatric Illness (TiC-P) was used to assess HCU in
the WEBCARE population.11 This generic patient self-report survey
includes 14 structured yes/no questions on relevantmedical resources
(eg, “Did you consult with a General Practitioner at any time during the
past three months”).11 Each item is followed by a question on the fre-
quency of utilization of that specific medical resource over the past 3
months. For example, thebaseline score represents theHCUwithin the
3 months prior to ICD implantation, while the 3-month score reflects
HCUbetweenbaseline and3monthspostimplantation. For the current
study, only the items referring to medical resource use (eg, General
Practitioner, company doctor, physiotherapist, and outpatient hospital
visits) were used, whereas current sample is not a psychiatric popula-
tion and psychological HCU was reported sporadically. The reliability
and validity of the medical resource items are considered satisfactory
(Cohen's kappa ranges from 0.597 to 0.795) within the population of
patients withmild tomoderatemental health problems,11 and is previ-
ously usedwithin the cardiac population.12
2.4 Anxiety
Symptoms of anxiety were assessed with the 7-item General Anxiety
Disorder scale (GAD-7). TheGAD-7 items (eg, “Feeling afraid, as if some-
thing awful might happen”) are rated on a 4-point Likert scale ranging
from 0 (not at all) to 3 (almost every day).13 The total score implies
severity of anxiety and ranges from 0 to 21, with higher scores indicat-
ing higher anxiety levels. With a Cronbach's alpha of 0.92, the internal
consistency of the GAD-7 is considered excellent.13
2.5 Depression
Depressive symptoms were assessed with the Patient Health Ques-
tionnaire (PHQ-9), a patient self-report survey which is comprised of
9 items (eg, “Feeling down, depressed, or hopeless”) that are answered
on a 4-point Likert scale ranging from 0 (not at all) to 3 (nearly every
day).14 The score range is between 0 and 27, with higher scores
representing a higher level of depression symptom severity. The
internal consistency is considered excellent, with Cronbach's alpha of
0.90.14
2.6 TypeD personality
Type D (distressed) personality was assessed with the DS14 (Type
D scale).15 This questionnaire consists of 14 items with two 7-item
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subscales measuring Social Inhibition (eg, “I find it hard to start a con-
versation”) and Negative Affectivity (eg, “I am often in a bad mood”).15
The items are rated on a 5-point Likert scale from 0 (false) to 4 (true).
The total score of both subscales range from 0 to 28. Patients are clas-
sified as TypeDwhen scoring≥10 on both subscales. The internal con-
sistency of SI and NA are considered satisfactory, with reported Cron-
bach's alphas of 0.86 and 0.88, respectively.15
2.7 Statistical analysis
Descriptive statistics of the baseline variables were evaluated using
frequencies (categorical variables) and mean scores with standard
deviations (SD) (continuous variables). They are presented as percent-
ages and means ± SDs, respectively. Differences between nonrespon-
ders and participants on baseline characteristics were calculated by
using the 𝜒2 test for independence (categorical variables) and inde-
pendent sample t-tests (continuous variables). Missing data were han-
dled by using pairwise deletion (available-case analysis). In order to
assess whether a priori determined demographic characteristics (age,
gender, and education), clinical variables (NYHA class, ICD indication,
total shocks [appropriate and inappropriate], CCI), and psychological
variables (anxiety, depression, and Type D personality) were associ-
ated with total HCU in ICD patients the first year after implantation,
a sum score was calculated for the number of healthcare use dur-
ing the 12-month period. Baseline measurement for the sum score
was excluded, as this score reflects HCU before the ICD implanta-
tion. Generalized linear modelling was used to investigate the change
in HCU over time. As HCU is considered count data, a Poisson dis-
tribution with log linear link function was used to model HCU scores
over time. Time was modelled as a continuous variable because the
intervals between the measurements were unequally spaced. A hier-
archical multivariable regression with three models was performed
in order to examine the predictors of HCU. Demographic charac-
teristics were entered in the first model. In the second model, clin-
ical variables were entered, followed by the psychological variables
in the third model. Subsequently, more detailed information about
the course of HCU over the year was provided by performing the
same analyses for time-point specific reported HCU at 3 (reflecting
HCU between baseline and 3 months follow-up), 6 (reflecting HCU
between 3 and 6 months follow-up), and 12 months (reflecting HCU
between 9 and 12 months follow-up) after ICD implantation, respec-
tively. All analyseswere conductedusing IBMSPSSStatistics 22.0 (IBM




A total of 1024 patients were approached for participation, with
562 patients being eligible and 340 patients signing the informed
consent. Of these 340 patients, 15% (51/340) did not return the
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F IGURE 1 Flowchart of patient recruitment [Color figure can be
viewed at wileyonlinelibrary.com]
follow-up, and 3% (9/280) passed away in the period between base-
line and 12 months follow-up (see Figure 1 for a detailed descrip-
tion of the sample selection). A total of 201 patients was included
in the current analyses. The majority of the patients were men
(274/340; 80.6%), with a mean age of 58 ± 10 years. Nonre-
sponders, compared to participants, were more likely to have a
NYHA functional class III/IV (58.1% vs 18.9%; 𝜒2 (1, 221) = 30.88,
P < 0.001, phi=−0.39), more likely to be diagnosedwith diabetesmel-
litus (35.5% vs 14.0%; 𝜒2 (1, 262)= 12.79, P < 0.001, phi=−0.23), and
more likely to have peripheral vascular disease (12.9% vs 4.5%; 𝜒2 (1,
262)=4.21,P=0.040,phi=−0.15). Adetailedoverviewof thebaseline
sample characteristics is presented in Table 1.
3.2 Healthcare utilization
The mean frequency of HCU (number of visits to General Practitioner,
companydoctor, physiotherapist, andoutpatient hospital visits),within
the first year following the ICD implantation, was 6.20 three months
after implantation (0 to 3 months), 5.36 at 6 months follow-up (3 to
6 months), and 4.76 12 months postimplantation (9 to 12 months),
respectively (Table 2). These HCU frequencies did not significantly dif-
fer across time (F (2, 680)= 2.738, P = 0.065).
3.3 Predictors of total HCUwithin 12months
postimplantation
Assessing the predictors of total HCU within 12 months post-
ICD implantation, analyses showed that sociodemographic variables
(Model 1) did not explain a significant part of the variance in HCU
(F (3, 155) = 0.91, P = 0.437, ∆R2 = 0.017). However, after adding
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TABLE 1 Baseline patient characteristics of the total sample
Variable Mean± SD; N (%)
Demographic
Age 58.16± 10.30
Gender (men) 274 (80.6)
Partner (yes)N= 288 244 (71.8)
Education level (High)N= 288 208 (61.2)
Work (yes)N= 288 141 (41.5)
Clinical
Heart failure (yes)N= 339 181 (53.2)
NYHA class III/IVN= 267 57 (21.3)
Ischemic heart disease (yes)N= 339 204 (60.0)
Atrial fibrillation (yes) N= 339 80 (23.5)
Secondary prevention indication N= 339 47 (13.8)
Any shocksa 28 (8.2)
Anemia (yes)N= 339 17 (5.0)
CVA in past N= 339 15 (4.4)
TIA in past N= 339 26 (7.6)
PAD N= 339 18 (5.3)
COPD (yes) N= 339 26 (7.6)
Diabetes mellitus (yes) N= 339 51 (15.0)
Dyslipidemia (yes) N= 339 71 (20.9)





Anxiety (GAD-7)N= 288 4.30± 4.54
Depression (PHQ-9) N= 289 5.45± 4.83
Type D personality (yes)N= 288 45 (13.2)
Cardiacmedication
Psychotrophics N= 339 33 (9.7)
ACE-inhibitors N= 339 206 (60.6)
Beta-blockers N= 339 279 (82.1)
Statins N= 339 209 (61.5)
Diuretics N= 339 172 (50.6)
Amiodarone N= 339 31 (9.1)
ACE = angiotensin-converting enzyme; COPD = chronic obstructive pul-
monary disease; CVA = cerebrovascular accident; GAD–7 = 7–item
General Anxiety Disorder scale; NHYA = New York Heart Association;
PAD= peripheral arterial disease; PHQ–9=Patient HealthQuestionnaire;
TIA= transient ischemic attack.
aShocks received between implantation and 12months.
TABLE 2 Overview of healthcare utilization over 12months
post-ICD implantation
Measurement point Mean± SD
HCUBaseline 5.39± 5.92
HCU 3months after implantation 6.20±7.89
HCU 6months after implantation 5.36± 7.34
HCU 12months after implantation 4.76± 7.38
HCU = healthcare utilization; ICD = implantable cardioverter defibrillator;
SD= standard deviation.
clinical characteristics (Model 2), the regression model improved sig-
nificantly (F (4, 151) = 2.02, P = 0.027, ∆R2 = 0.068) and explained
9% of the total variance in HCU. Age (𝛽 = -0.187, P = 0.029), NYHA
class (𝛽 = 0.179, P = 0.026), and CCI (𝛽 = 0.176, P = 0.034) emerged
as independent predictors of postimplantationHCU.With the addition
of psychological variables (Model 3), 15% of the variance in HCU was
explained (F (3, 148) = 2.67, P = 0.010, ∆R2 = 0.067), adding to the
level of prediction of themodel. Of all the predictors in the final model,
only depression appeared to be significantly associatedwith totalHCU
(𝛽 = 0.342, P = 0.002). This association indicates that higher depres-
sion scores at baseline are associated with higher HCU the first year
postimplantation, independent of demographic, clinical, and psycho-
logical variables (see Table 3 for a detailed overview of the regression
model).
3.4 HCU at 3, 6, and 12months
3.4.1 Baseline–3months follow-up
Assessing the predictors of HCU within the first 3 months post-
ICD implantation revealed that sociodemographic characteristicswere
not associated with HCU (Model 1: F(3, 177) = 1.91, P = 0.130,
∆R2 = 0.031). In Model 2, clinical characteristics were added to the
sociodemographic characteristics and this model explained 10% of the
total variance in HCU (F (4, 173) = 2.65, P = 0.016, ∆R2 = 0.066).
Younger age (𝛽 = −0.220, P = 0.006), NYHA class III/IV (𝛽 = 0.188,
P = 0.012), and secondary indication for ICD (𝛽 = 0.148, P = 0.045)
were independent predictors in thismodel. Adding anxiety, depression,
and Type D personality in Model 3 did not significantly increase the
explained variance in HCU (F (3, 170) = 2.15, P = 0.406, ∆R2 = 0.015).
Younger age (𝛽 = -0.226, P = 0.005), NYHA class III/IV (𝛽 = 0.163,
P = 0.035), and secondary indication for an ICD (𝛽 = 0.145, P = 0.049)
remained significant predictors of HCU. See Table 3 for a detailed
overview.
3.4.2 Three to 6months follow-up
ForHCUbetween3and6months postimplantation, demographic vari-
ables (Model 1) did not explain a significant proportion of the variance
(F (3, 184) = 1.34, P = 0.263,∆R2 = 0.021). When adding clinical char-
acteristics in Model 2, the model did not explain a significant propor-
tion of the variance (F (4, 180)=1.96,P=0.052,∆R2 =0.049). Younger
age (𝛽 = −0.177, P = 0.024) and CCI (𝛽 = 0.157, P = 0.039) were sig-
nificantly associated with HCU. Sociodemographic, clinical, and psy-
chological characteristics combined in Model 3 accounted for a sig-
nificant 15% of the variance in HCU (F (3, 177) = 3.04, P = 0.002,
∆R2 = 0.076). In this model, younger age (𝛽 = −0.151, P = 0.050) and
depression (𝛽 =0.370,P<0.001)were associatedwith increasedHCU,
independent of other demographic, clinical, and psychological vari-
ables (see Table 3).
3.4.3 Six to 12months follow-up
Between 6 and 12 months, sociodemographic characteristics in
Model 1 were not associated with HCU (F (3, 170) = 0.72, P = 0.544,














TABLE 3 Predictors of HCU over the entire 12months, at 3, 6, and 12months after ICD implantation
Total 3months 6months 12months
B SEB B B SEB 𝜷 B SEB 𝜷 B SEB 𝜷
Model 1:
Age −0.241 0.156 −0.129 −0.135 0.059 −0.177* −0.091 0.054 −0.128 0.023 0.057 0.032
Gendera 0.596 4.001 0.012 −0.702 1.525 −0.035 −0.930 1.398 −0.050 1.858 1.469 0.100
Educationb −1.380 3.494 −0.032 0.428 1.332 0.024 −1.641 1.221 −0.099 1.037 1.283 0.063
Model 2:
Age −0.348 0.158 −0.187* −0.169 0.060 −0.220** −0.126 0.056 −0.177* −0.007 0.059 −0.009
Gender 0.405 4.002 0.008 −0.779 1.524 −0.039 −0.989 1.410 −0.053 2.054 1.502 0.110
Education −0.540 3.432 −0.012 0.689 1.307 0.039 −1.363 1.209 −0.083 1.300 1.288 0.078
CCI 3.611 1.683 0.176* 1.055 0.641 0.125 1.235 0.593 0.157* 1.302 0.632 0.165
NYHA class 8.385 3.741 0.179* 3.607 1.424 0.188* 2.512 1.318 0.140 0.128 1.404 0.007
ICD
indicationc
2.389 1.851 0.102 1.421 0.705 0.148* 0.803 0.652 0.090 −0.115 0.695 −0.013
Total shocksd −0.180 2.712 −0.005 −0.030 1.033 −0.002 −0.340 0.955 −0.026 0.076 1.018 0.006
Model 3:
Age −0.306 0.156 −0.164 −0.173 0.061 −0.226** −0.107 0.054 −0.151* 0.019 0.058 0.026
Gender −1.650 3.960 −0.034 −.882 1.551 −0.044 −1.851 1.387 −0.100 1.088 1.479 0.058
Education −0.760 3.358 −0.018 0.499 1.316 0.028 −1.430 1.176 −0.087 1.339 1.254 0.081
CCI 3.277 1.683 0.159 1.160 0.659 0.137 1.056 0.589 0.135 1.068 0.629 0.135
NYHA class 5.652 3.760 0.121 3.127 1.473 0.163* 1.391 1.317 0.078 −0.866 1.404 −0.048
ICD indication 2.379 1.801 0.101 1.399 0.706 0.145* 0.799 0.631 0.089 −0.100 0.673 −0.011
Total shocks −.446 2.642 −0.013 −0.071 1.035 −0.005 −0.459 0.925 −0.035 −0.018 0.987 −0.100
Anxietye −0.621 0.441 −0.146 −0.196 0.173 −0.112 −0.254 0.155 −0.157 −0.148 0.165 −0.091
Depressionf 1.362 0.422 0.342* 0.186 0.166 0.114 0.561 0.148 0.370** 0.542 0.158 0.355**
Type D
personalityg
−6.795 4.347 −0.128 −1.833 1.703 −0.084 −2.301 1.522 −0.114 −2.317 1.623 −0.114
aMale vs female.
bHigh vs low level.
cSecondary vs primary indication.
dtotal shocks (both appropriate and inappropriate) received between implantation and 12months
eContinuous.
fContinuous.
gType D personality vs non-Type D personality.
Total: R2 = 0.02 for model 1,ΔR2 = 0.07 (P= 0.03) for model 2,ΔR2 = 0.07 (P= 0.01) for model 3.
3months: R2 = 0.03 for model 1,ΔR2 = 0.07 (P = 0.02) for model 2,ΔR2 = 0.02 (P= 0.41) for model 3.
6months: R2 = 0.02 for model 1,ΔR2 = 0.07 (P= 0.05) for model 2,ΔR2 = 0.08 (P< 0.01) for model 3.
12months: R2 = 0.01 for model 1.ΔR2 = 0.03 (P = 0.36) for model 2,ΔR2 = 0.08 (P< 0.01) for model 3.
h*P≤ 0.05.
i**P≤ 0.01.
CCI=Charlson Comorbidity Index (continuous); HCU= healthcare utilization; ICD= implantable cardioverter defibrillator; NYHA class=NewYork Heart Association functional class (III–IV vs I–II).
444 BROERS ET AL.
significantly improve the level of prediction of the model (F (4,
166) = 0.94, P = 0.358, ∆R2 = 0.026). When combining sociode-
mographic, clinical, and psychological characteristics in Model 3, a
significant 12%of the variance inHCUwas explained (F (3, 163)=2.13,
P=0.003,∆R2 =0.078). Depression (𝛽 =0.355,P=0.001)was the only
variable associated with increased HCU independent of demographic,
clinical, and psychological variables (see Table 3).
Although the influence of depression onHCUwas larger at 6 and12
month than at 3months, these differences failed to reach significance.
4 DISCUSSION
To our knowledge, this is the first study to tap into HCU and its predic-
tors in patients with an ICD. The results of the current study showed
that HCUwas the highest between baseline and 3months postimplan-
tation and that it gradually decreased over the 12-months follow-up.
Focusing on the predictors of HCU, the results showed that for total
HCU in the first year postimplantation only depression was a signifi-
cant predictor after controlling for demographic and clinical variables.
When focusing on HCU within the first 12 month postimplantation,
analyses showed that between baseline and 3 months postimplanta-
tion, younger age, NYHA class, and secondary indication were asso-
ciated with increased HCU, adjusting for baseline demographic and
clinical and psychological characteristics. However, between 3 and 6
months postimplantation only younger age and depression were sig-
nificant predictors of HCU after controlling for other relevant vari-
ables. In addition, between6and12monthsonlydepressionwas signif-
icantly associated with increased HCU independent of other relevant
variables.
The current findings are in line with some previous studies in
the general cardiac population that focused on HCU. For example,
in patients with chronic stable angina, depression was an indepen-
dent predictor of an increase in mean cumulative 1-year healthcare
costs, with a 33% increase in patients with depression as compared
to non-depressed patients.16 This increase was observed in several
healthcare sectors after controlling for other healthcare expendi-
ture costs (eg, physician costs, outpatient care, chronic care, inpa-
tient care, and medications).16 A possible mechanism underlying the
association between depression and HCU is the association between
depression and unhealthy lifestyle behaviors (eg, smoking, reduced
exercise, unhealthy diet, alcohol consumption, and sedentary lifestyle),
as depression is a known barrier for lifestyle changes, whichmay result
in poor physical health and eventually in increased HCU.17 In addition,
patients with depression may experience associated somatic symp-
toms (eg, headaches, sleep disturbances) for which additional care is
sought. Another explanation could be that depressed cardiac patients
obtain lower quality of care as compared to cardiac patients who are
not depressed.18 This may lead to undertreatment of these patients,
resulting in more physical complaints as a consequence. Remarkably,
in contrastwith existing literature on the relation between anxiety and
high HCU in both cardiac and noncardiac populations,19,20 the cur-
rent study did not find this association. The relatively healthy recruited
population could possibly explain this. Furthermore, the majority of
patients in the current sample received beta-blockers as part of their
cardiac medication regimen.21 As beta-blockers are known for their
anxiolytic properties,22 this may have further reduced anxiety lev-
els. Speculatively, one might also reason that increased anxiety levels
might lead to less medical resource seeking as part of an avoidant cop-
ing strategy.
Within the ICD population specifically, appropriate and inappropri-
ate shocks are well known predictors of HCU.23,24 Yet, in our study,
only 8% of the total sample received a shock of any kind, which may
explain why no association between shocks and HCU within the pre-
dictor models was found. Nevertheless, it would be valuable for future
research to conduct a sub analysis in a larger sample with only ICD
recipients who have received shocks, exploring the specific contribu-
tion of appropriate and inappropriate shocks to HCU. Previous stud-
ies found older age and comorbidities9 to be predictors of increased
HCU. By contrast, our results showed that younger age was associ-
ated with increased HCU, while no association was found with comor-
bidities. Again, a possible explanation for the latter could be that the
WEBCARE sample was relatively healthy. With respect to age, within
the ICD population younger age has been associated with poor adjust-
ment postimplantation and increased distress.25 As discussed previ-
ously, this may lead to increase of somatic symptoms and associated
HCU.
The outcomes of this study stress the necessity for clinicians to be
alert to signs of depression (eg, sadness, loss of interest, withdrawing
from relatives, nonadherence to treatment, etc.), particularly as of 3
months post-ICD implantation. Since studies show that psychological
interventions like cognitive behavioral therapy are beneficial in reduc-
ing depressive symptoms in ICD patients,26 referral for psychological
help in case of a suspectedmood disorder is warranted.
The results of the current study must be interpreted with the
following limitations in mind. HCU was assessed using the TiC-P self-
report questionnaire. While this is easy and low-cost to use, it may be
prone to recall bias and therefore not an entirely accurate representa-
tion of HCU. Furthermore, the TiC-P questionnaire has been designed
for psychiatric populations and has not been validated for cardiac
patients. Therefore, future research should usemoreobjective sources
of information to quantify HCU. In addition, HCU over 12 months
may be underestimated. As the TiC-P questionnaire assesses HCU 3
months in retrospect, at month 12 the scores reflect HCU between
month 9 and 12. As in the WEBCARE study no assessment took place
at 9 months; we were not able to assess the level of HCU between
6 and 9 months postimplant. Furthermore, as mentioned previously
the WEBCARE sample was relatively higher educated and healthy as
compared to other ICD samples. Thismight have influenced the results
and their generalizability to the general ICD population. Final, given
improvements in technology of the ICD during the last decade, the
representativeness of the WEBCARE cohort for the current ICD
population might be questionable. These innovations have led to a
reduction in shocks, and could therefore have an influence on the
generalizability of current findings. However, similar levels of depres-
sion have been reported by a study in ICD recipients that did use new
programming strategies.27 This study also have some advantages.
It is the first study to examine HCU in the ICD population, using a
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prospective study design in a well-described population. In addition,
research shows that only a small number of high-cost utilizers in
general keeps usingmedical resources after a year.9
Future studies are warranted that focus on the mechanisms under-
lying the association between depression and HCU. In addition, it
would be valuable to examine which patient profiles are associated
with increased HCU in order to develop programs that could provide
more personalized care at the right time. Finally, research is warranted
to replicate the current findings, using more objective indicators of
HCUand associated costs and comparewhether there is a discrepancy
between objective and subjective indicators of HCU.
In conclusion, this study showed that depression is an important
predictor of HCU in ICD patients within the first 12 months postim-
plantation. The impact of depression on HCU is particularly promi-
nent from 3months and up to 12months postimplantation.Within the
first 3months, younger age,NYHAclassification (III-IV), and secondary
indication showed to be associated with HCU. Future research should
focus identifying patientswho need additional care and provide this on
time in order to better meet patients’ needs and lower future HCU.
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